The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Over The Period 2026–2030?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size has experienced rapid expansion in recent years. Its value is projected to rise from $8.41 billion in 2025 to $9.68 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.1%. The increase observed in the historic period can be ascribed to elements like covid 19 vaccine programs, the expansion of biotech startups, insufficient in house manufacturing capacity, an increase in contract manufacturing, and swift mrna platform validation.
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size is anticipated to experience substantial growth in the upcoming years. This market is projected to reach $17.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.3%. Such expansion during the forecast period is attributable to several factors, including the proliferation of mrna cancer vaccines, the rise of personalized vaccines, an increase in cdmo collaborations, the need for expedited manufacturing capabilities, and a growing pipeline of mrna therapies. Key trends anticipated in this period encompass lipid nanoparticle formulation services, accelerated mrna process scaling, comprehensive fill-finish outsourcing solutions, adaptable modular vaccine manufacturing suites, and complete end-to-end mrna development services.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33214&type=smp
What Drivers Are Influencing The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
The increasing occurrence of infectious and novel diseases is anticipated to boost the expansion of the mRNA vaccine CDMO market in the future. These diseases are conditions resulting from disease-causing microorganisms that either spread quickly or appear for the first time, influenced by elements like environmental shifts, urban development, and enhanced global connections. Increased global travel, higher population concentrations, and intertwined supply networks have accelerated the spread of pathogens, leading to more frequent, widespread, and challenging-to-control disease outbreaks. mRNA vaccine CDMOs are crucial in tackling these issues, facilitating the swift creation, expandable production, and adaptable manufacturing of vaccines essential for countering evolving infectious dangers. Given that mRNA technologies demand specific manufacturing facilities and specialized technical know-how, vaccine developers often partner with contract development and manufacturing organizations to speed up development schedules and guarantee production capability during outbreaks. For example, in May 2024, data from the World Health Organization (WHO), the Switzerland-based United Nations’ specialized agency focusing on global health, indicated that by 30 April 2024, the WHO had received reports of over 7.6 million dengue cases worldwide, comprising 3.4 million confirmed cases, more than 16,000 severe cases, and over 3,000 fatalities. This surge was especially noticeable in the Region of the Americas, where the number of cases surpassed seven million by April 2024, exceeding the entire 2023 annual total of 4.6 million cases. Consequently, the growing incidence of infectious and emerging diseases is fueling the expansion of the mRNA vaccine CDMO market.
How Is The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Divided Into Its Major Segments?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development; Manufacturing; Analytical And Quality Control; Fill Finish; Packaging; Other Service Types
2) By Vaccine Type: COVID-19 Vaccines; Cancer Vaccines; Infectious Disease Vaccines; Other Vaccine Types
3) By Scale of Operation: Preclinical; Clinical; Commercial
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Formulation Optimization; Cell Line Development; Upstream Process Development; Process Scale-Up
2) By Manufacturing: Lipid Nanoparticle Production; Enzymatic Capping; Purification Process
3) By Analytical And Quality Control: Potency Testing; Purity Analysis; Stability Testing; Identity Testing; Microbial Testing
4) By Fill Finish: Aseptic Filling; Vial Filling; Syringe Filling; Lyophilization
5) By Packaging: Primary Packaging; Secondary Packaging; Labeling Operations; Cold Chain Packaging; Unit Dose Packaging
6) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Contract Development Services; Consulting Services; Supply Chain Management
How Are Trends Transforming The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Landscape?
Major companies in the mRNA vaccine CDMO market are increasingly concentrating on advanced innovations, such as phase-appropriate GMP mRNA contract development and manufacturing services. These initiatives are designed to accelerate preclinical and IND-enabling development, all while maintaining regulatory-aligned quality standards and achieving shorter timelines. Phase-appropriate GMP-like mRNA manufacturing refers to a production method that delivers high-quality, regulatory-aware mRNA material suitable for preclinical and early development stages, without the expenses and operational complexities associated with comprehensive GMP manufacturing. For example, in May 2025, GenScript Biotech Corporation, a China-based global biotechnology reagents and services provider, launched a GMP-like mRNA manufacturing service specifically to support preclinical and IND-enabling development. This service provides high-quality, regulatory-aware mRNA with reduced lead times and lower costs compared to traditional full GMP manufacturing, thereby reflecting the growing demand for adaptable, phase-appropriate CDMO solutions in the mRNA vaccine market.
Which Key Industry Participants Are Active In The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH
Read the full messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market report here:
Which Region Is Anticipated To See The Fastest Growth In The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the mRNA vaccine contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33214&type=smp
Browse Through More Reports Similar to the Global Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company
Vaccine Contract Manufacturing Market Report 2026
Mrna Cancer Vaccines And Therapeutics Market Report 2026
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model